The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Copy number features as a novel biomarker of homologous recombination (HR) status in high-grade serous ovarian cancer (HGSOC).
 
Paula Romero Lozano
No Relationships to Disclose
 
Maria Vila-Casadesús
No Relationships to Disclose
 
Judit Matito
No Relationships to Disclose
 
Carmen García-Duran
No Relationships to Disclose
 
Deborah Grazia Lo Giacco
No Relationships to Disclose
 
Marina Gómez-Rey
No Relationships to Disclose
 
Juan Francisco Grau
No Relationships to Disclose
 
Lorena Fariñas-Madrid
No Relationships to Disclose
 
Eva Hernández-Illán
No Relationships to Disclose
 
Agatha Martin
No Relationships to Disclose
 
Cecília García
No Relationships to Disclose
 
Ester Castillo
No Relationships to Disclose
 
Josep Maria Miquel Aymar
No Relationships to Disclose
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Avvinity; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc
Other Relationship - Imedex; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera; Eisai; EMD Serono; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Medison; Merck Sharp & Dohme; Mersana; Novocure; PharmaMar; prIME Oncology; Roche; Roche; Shattuck Labs; Sutro Biopharma; Tesaro
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Belgian Gynaecological Oncology Group (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Medimmune (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Mundipharma Research (Inst); Novartis Farmacéutica (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Ana Vivancos
Stock and Other Ownership Interests - Reveal Genomics
Consulting or Advisory Role - Bayer (Inst); Bristol-Myers Squibb (Inst); Guardant Health (Inst); Incyte (Inst); Merck (Inst); Roche (Inst)
Research Funding - Bristol Meyers Squibb (Inst); Incyte (Inst); Roche (Inst)